GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » EPS without NRI
中文

Regencell Bioscience Holdings (Regencell Bioscience Holdings) EPS without NRI : $-0.45 (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings EPS without NRI?

Regencell Bioscience Holdings's earnings per share without non-recurring items for the six months ended in Jun. 2023 was $-0.20. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -91.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Regencell Bioscience Holdings's EPS without NRI or its related term are showing as below:

RGC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -165.5   Med: -128.55   Max: -91.6
Current: -91.6

During the past 5 years, Regencell Bioscience Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -91.60% per year. The lowest was -165.50% per year. And the median was -128.55% per year.

RGC's 3-Year EPS without NRI Growth Rate is ranked worse than
97.96% of 832 companies
in the Drug Manufacturers industry
Industry Median: 11.65 vs RGC: -91.60

Regencell Bioscience Holdings's EPS (Diluted) for the six months ended in Jun. 2023 was $-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.

Regencell Bioscience Holdings's EPS (Basic) for the six months ended in Jun. 2023 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.45.


Regencell Bioscience Holdings EPS without NRI Historical Data

The historical data trend for Regencell Bioscience Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings EPS without NRI Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
EPS without NRI
-0.03 -0.06 -0.11 -0.58 -0.45

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EPS without NRI Get a 7-Day Free Trial Premium Member Only -0.08 -0.29 -0.29 -0.25 -0.20

Competitive Comparison of Regencell Bioscience Holdings's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's PE Ratio without NRI falls into.



Regencell Bioscience Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regencell Bioscience Holdings  (NAS:RGC) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Regencell Bioscience Holdings EPS without NRI Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus